^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:KO-947 (ERK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    First-in-Human Study of KO-947 in Non-Hematological Malignancies

    Excerpt:
    ...Malignancy of non-squamous histology that carries a BRAF, KRAS, NRAS or HRAS mutation(s)....
    Trial ID:
    NCT03051035
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Research
    Title:

    Abstract 5168: KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors

    Excerpt:
    KO-947 blocks ERK signaling and proliferation of tumor cells exhibiting dysregulation of MAPK pathway signaling, including mutations in BRAF, NRAS or KRAS, at low nanomolar concentrations...In cell-line derived xenograft studies, the drug profoundly suppresses ERK signaling for up to five days after a single dose and induces regressions in RAS- and RAF-mutant melanoma, NSCLC and pancreatic cancer models on administration schedules ranging from daily to weekly.
    DOI:
    10.1158/1538-7445.AM2017-5168